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ABSTRACT 
 Alzheimer's Disease (AD) and Parkinson's Disease (PD) are both progressive 
neurodegenerative disorders that affect millions of Americans and for which there are no cures. 
AD can significantly impair the ability to think, remember, communicate, and carry out daily 
activities, while PD can affect motor functions such as balance, coordination, and the ability to 
speak. Intracellular protein aggregation is a hallmark of both diseases, with AD being 
characterized by the build up of neurofibrillary tangles composed of misfolded tau protein and 
PD being characterized by Lewy bodies composed of alpha-synuclein. Both normal tau and 
alpha-synuclein can localize to the nucleus; however, their nuclear roles have not been fully 
elucidated. These proteins bind and stabilize alternative DNA structures, which form most 
readily at purine-pyrimidine repeats. The 1f promoter of the Nitric Oxide Synthase I (NOSI) 
gene, which is misregulated in both AD and PD, contains one such repeat. This NOSI repeat is 
polymorphic and has the sequence (TG)mTA(TG)n where m and n can vary from individual to 
individual. Genotyping shows that shorter dinucleotide polymorphisms are associated with AD 
and PD. Promoters with shorter repeats also have decreased transcriptional expression compared 
to promoters with larger repeats. Because tau and alpha-synuclein can bind such repeats, we 
hypothesize that tau and alpha-synuclein may modulate NOSI transcription through the 
(TG)nTA(TG)m repeat. Reporter genes directed by the NOSI 1f promoter with and without the 
(TG)nTA(TG)m repeat region were transfected into human neuroblastoma cells (SK-N-MC) and 
human cervical cancer cells (HeLa) that express varying levels of tau and alpha-synuclein. 
Promoters with the TG repeat directed approximately two-fold changes in reporter gene 
expression, while promoters without the TG repeat caused no change in expression. These 
findings suggest that tau and alpha-synuclein modulate NOSI expression through interaction with 
a dinucleotide polymorphism associated with disease development. 	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BACKGROUND 
Both Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are progressive, 
neurodegenerative disorders which account for millions of deaths each year (Centers for Disease 
Control and Prevention, 2015). The severe and debilitating nature of AD and PD make it 
imperative that we investigate the molecular mechanisms underlying neurodegeneration. AD and 
PD are similar in that they are both characterized by protein misfolding which leads to protein 
aggregation. Misfolded tau and alpha-synuclein accumulate in potentially pathogenic 
intracellular neurofibrillary tangles in AD and PD, respectively (Vasudevaraju et al., 2012). 
Understanding the normal function of tau and alpha-synuclein is critical in understanding the 
pathology of these neurodegenerative diseases.  
In neurons, tau, short for tubulin associated factor, functions to maintain microtubule 
stability which is critical for cellular transport through axons (Duan et al., 2012). 
Hyperphosphorylation causes tau to dissociate from microtubules, allowing the microtubules to 
depolymerize. The free hyperphosphorylated tau is truncated and can then aggregate into 
neurofibrillary tangles (Mania et al., 2015; Frost et al., 2014; Duan et al., 2012 & Lee et al., 
2001). It is unclear whether free truncated tau or the neurofibrillary tangles themselves are more 
toxic to the cell. Some studies suggest that neurofibrillary tangles are toxic, while others suggest 
that neurofibrillary tangles are a cellular protective mechanism against free truncated tau (Mania 
et al., 2015). 
Alpha-synuclein is a neuron-specific protein localized primarily in the nucleus and 
presynaptic nerve terminals (Maroteaux et al., 1988). Its exact function in the cell is still 
unknown; however, many studies suggest significant implications of α-synuclein in synaptic 
transmission (Cabin et al., 2002). A missense mutation in the gene that encodes alpha-synuclein 
(SNCA) was associated with familial cases of early-onset PD. The mutation in SNCA is one 
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potential cause of Lewy Body formation and is thought to disrupt secondary protein structure 
leading to self-aggregation of alpha-synuclein (Polymeropoulos et al., 1997). Alpha-synuclein 
has since been studied in the contexts of PD pathogenesis, but the exact role of the protein in 
neurodegeneration has yet to be elucidated.   
Much research on AD and PD has focused on the roles of tau and alpha-synuclein in the 
cytoplasm; however, focusing only on these tangles has failed to fully explain the mechanisms 
behind neurodegeneration. Therefore, our study examines the role of tau and alpha synuclein in 
the nucleus.	  Unphosphorylated tau and alpha-synuclein localize to the nucleus. Although their 
nuclear binding site has yet to be elucidated, several studies suggest they bind preferentially to 
purine-pyrimidine repeats in the DNA (Sultan et al., 2011; Vasudevaraju et al., 2012 & Liu and 
Gotz, 2013). Purine-pyrimidine repeats can often be found in promoter regions where 
transcription of the gene produces negative supercoils, which can cause the DNA in the repeat 
region to switch into alternative forms (Cox et al., 2012). Furthermore, one study showed that 
the tau protein is capable of binding and stabilizing a CG oligonucleotide in the Z-DNA 
conformation, while alpha-synuclein stabilizes the oligonucleotide in an altered B-DNA 
conformation (Vasudevaraju et al., 2012). Circular dichroism studies have detected Z-DNA in 
post-mortem AD brains, while DNA isolated from PD brains is far more likely to contain altered 
B-DNA structures, which do not match any currently crystallized forms of DNA (Vasudevaraju 
et al., 2012). Thus, tau may be responsible for changes in the DNA structure observed in AD, as 
well as alpha-synuclein in PD.   
Because these changes in DNA structure are occurring in promoter regions, they are 
likely to affect transcription factor access to the DNA. Thus, tau and alpha-synuclein induction 
or stabilization of alternate DNA structures could affect transcription of the genes with purine-
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pyrimidine repeats within their promoter regions (Vasudevaraju et al., 2012). The Nitric Oxide 
Synthase I gene (NOSI), which is misregulated in both AD and PD, contains a purine-pyrimidine 
repeat in its promoter region. Therefore, it is a good model to study the ability of tau and alpha-
synuclein to modulate gene expression at purine-pyrimidine repeats.  
Many studies associate the misregulation of NOSI with neurodegenerative disorders 
including AD and PD (Knott and Bossy-Wetzel, 2009 and Przedborski et al., 1996). The NOSI 
enzyme produces secondary messenger nitric oxide (NO), which is crucial for the regulation of a 
variety of body functions including controlling blood pressure, long-term memory, synapse 
formation, pain regulation, muscle movement, glucose regulation, and urine formation (Toda and 
Okamura, 2003; & Prast, 2001).  The most direct link between NOSI and neurodegenerative 
disease was discovered using the MPTP mouse model. Mice treated with MPTP develop PD-like 
symptoms, while NOSI-deficient mice treated with MPTP do not develop PD symptoms 
(Przedborski et al., 1996). These findings suggest that NOSI plays a role in MPTP-induced 
neurotoxicity. NOSI transcription must be tightly regulated, as excess NO can have neurotoxic 
effects, while low levels can have neuroprotective effects (Sultana et al., 2006).  Thus, 
transcriptional misregulation of NOSI likely contributes to the pathology of AD and PD, making 
it important to examine the NOSI promoter. 
Transcriptional regulation of NOSI is highly complex but has not been extensively 
studied. The human NOSI gene, located on chromosome 12, is over 160 kb in length and consists 
of 29 exons (Hall et al., 1994). Of these 29 exons, 12 first exons (1a-l) controlled by 12 separate 
first promoters are alternatively spliced to exon 2, which contains the translation start site (Rife 
et al., 2009). Expression of the different first exons is tissue specific with first exons 1d, 1f, and 
1g predominating in the brain (Bros et al, 2006). This study focuses on the human 1f promoter, 
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which contains a polymorphic purine-pyrimidine repeat, (TG)mTA(TG)n (Figure 2). Shorter 
lengths of this purine-pyrimidine repeat correlate with a higher risk of both AD and PD 
(Galimberti et al., 2008, Rife et al., 2009). Previous gene expression assays revealed that NOSI 
constructs containing the polymorphic (TG)mTA(TG)n repeat change their expression in response 
to tau knockdown as well as alpha-synuclein overexpression. These studies also showed that 
longer repeats respond more than shorter repeats to changing levels of tau and alpha-synuclein, 




Figure 1. Map of human NOSI gene and an example mRNA transcript. A) Schematic of the 
12 first exons that are alternatively spliced to the protein coding exons 2-29. B) Example mRNA 
transcript of exon 1f spliced to exon 2 with a marked translation start site in exon 2. C) Sequence 
of NOSI 1f promoter region from GenBank reference numbers 1441-1655 containing the 
polymorphic (TG)mTA(TG)n repeat. The repeat is shown in pink, and the TATA box is shown in 
blue. Figure 1A and 1B were obtained from Logan Murphy. 
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Hypothesis:  
In summary, the tau protein creates neurofibrillary tangles in AD neurons, while alpha-
synuclein creates tangles in PD neurons. Studies have shown that both of these proteins can enter 
the nucleus and bind preferentially to purine-pyrimidine repeats, a common site for altered DNA 
structures found in AD and PD brains (Vasudevaraju et al. 2012). The NOSI gene, which is 
known to be misregulated in both AD and PD, contains a polymorphic thymine-guanine repeat in 
its 1f promoter. Because shorter repeats are more highly correlated with AD and PD and because 
varying length repeats express differently in response to tau and alpha-synuclein, we hypothesize 
that tau and alpha-synuclein are modulating the expression of NOSI through this 
(TG)mTA(TG)n  repeat.  
To test our hypothesis, we created and tested three new NOSI promoter deletion 
constructs and compared expression of their luciferase reporter gene to that of an already existing 
full length NOSI 1f promoter under high and low tau and alpha-synuclein levels. The Full 
Promoter construct contains a 54 bp (TG)mTA(TG)n repeat while the ΔTG construct includes the 
entire promoter excluding only the (TG)mTA(TG)n (Figure 2). If tau or alpha-synuclein act 
through the TG repeat, then we expect no change in expression in the ΔTG construct when tau or 
alpha-synuclein levels are changed. We also made two 5' deletion constructs of the full promoter 
– Δ5’ Region and Δ5’ Region & TG. The Δ5’ Region construct contains the entire 
(TG)mTA(TG)n repeat with no upstream sequences and the Δ5’ Region &TG construct has no 
repeat or upstream sequences (Figure 2). Expression assays with construct Δ5’ Region allow us 
to either rule out or consider the upstream region of the NOSI promoter as a potential site of 
regulation for tau and alpha-synuclein. Because this construct includes the 
(TG)mTA(TG)n  repeat, we expect Δ5’ Region to exhibit similar expression changes to the Full 
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Promoter construct when tau and alpha-synuclein are differentially expressed. The Δ5’ Region & 
TG construct will allows us to narrow down whether tau and alpha-synuclein could be regulating 
transcription through only the region downstream of the (TG)mTA(TG)n  repeat. We expect this 
construct to exhibit no expression changes when tau is knocked-down or alpha-synuclein 
overexpressed. However, if ΔTG or Δ5’ Region & TG change expression in response to 
differential tau and alpha-synuclein expression, we will have to consider other regions of the 
NOSI promoter as potential sites of regulation for these proteins. 
 
 
Figure 2. Schematic of the human NOSI 1f promoter with modified clones used in this 
study. The full NOSI promoter containing the (TG)14TA(TG)12 repeat was obtained from the 
Young lab at Ohio State University. Light pink bars indicate the regions upstream of the 
(TG)14TA(TG)12 repeat while dark pink bars indicate regions downstream of the (TG)14TA(TG)12 
repeat. Red flags indicate GenBank Reference numbers where deletions were made. The ΔTG, 
Δ5’ Region, and the Δ5’Region & TG constructs were cloned into a pGL3 luciferase reporter 












Δ 5’ REGION & TG
FULL NOSI PROMOTER(TG)14TA(TG)12
18341502 1567
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METHODS: 
Cloning:     
 
PCR using the Full Promoter as a template was performed to obtain truncated NOSI 
promoters for cloning into pGL3 luciferase vectors. Table 1 contains the primers designed to 
amplify the targeted promoter regions. The ΔTG required three rounds of PCR to stitch 
nucleotides 1-1504 to nucleotides 1567-1834 (Figure 3), while constructs Δ5’ Region and Δ5’ 
Region & TG required only one round of PCR (Figure 4).  
 
Figure 3. Schematic of PCR for the ΔTG construct. The pink lines represent the NOSI Full 
Promoter, and the maroon lines represent the (TG)14TA(TG)12 repeat. Reaction 1 produces the 
upstream and downstream region of the ΔTG construct that will be attached to remove the 
(TG)14TA(TG)12 repeat. The light gray 5’ overhangs of theΔTG Fwd and ΔTG Rev primers 
contain sequence from the other side of the repeat that is being removed; these overhangs also 
contain regions that are complementary to each other and will bind as shown in ΔTG Reaction 2. 
The forward and reverse primers containing a KpnI and BglII site, respectively, are utilized so 
that ΔTG can be cloned into pGL3.  
 
ΔTG Reaction 2
Fwd primer with KpnI site




ΔTG  Fwd primer





Rev primer with BglII siteFwd primer with KpnI site
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Figure 4. Schematic of PCR for constructs Δ5’ Region and Δ5’ Region & TG. The pink lines 
represent the NOSI Full Promoter, and the maroon lines represent the (TG)14TA(TG)12 repeat. 
The forward primer for Δ5’ Region binds to the TG repeat, while the forward primer for Δ5’ 
Region & TG binds directly after the TG repeat. The reverse primer binds to the downstream 
region of the Full Promoter, and the 5’ region of the reverse primer contains a hanging BglII 
restriction site to allow for cloning into pGL3.  
 
Table 1. Forward and reverse primer sequences used to clone various regions of the NOSI 
promoter. ΔTG requires three reactions while Δ5’ Region and Δ5’ Region & TG require one. 
KpnI sites are indicated in red, while BglII sites are indicated in blue. The dark grey forward 
primers both contain the same sequence, and the light grey reverse primers contain the same 
sequence. 
 
Reaction/Construct Forward Primer Sequence (5’ to 3’) Reverse Primer Sequence (5’ to 3’) 
ΔTG Reaction 1a GGGGTACCAAGCTTGTGCTCCCAGAG GAGGGTCTTTAACAGTAAAAGG 
ΔTG Reaction 1b GTCATTTTCGTGATAGAAAAAAAA CACTCCTCGATGAATCGCGTCTAGAAG 
ΔTG Reaction 2 Nested PCR using complementary products from ΔTG 1a and ΔTG 1b 
ΔTG Reaction 3 GGGGTACCAAGCTTGTGCTCCCAGAG CACTCCTCGATGAATCGCGTCTAGAAG 
Δ5’ Region CATTGTGTGTGTGTGTGTGTGTGTGTGTGT CACTCCTCGATGAATCGCGTCTAGAAG 
Δ5’ Region & TG TTTCCTGATAGAAAAAAAAAAATGG CACTCCTCGATGAATCGCGTCTAGAAG 
Sequencing Primer 1 CTTTATGTTTTTGGCGTCTTCCA 
Sequencing Primer 2 CTAGCAAAATAGGCTGTCCC 
 
Each polymerase chain reaction mixture contained 1X high fidelity PCR buffer, 0.2 mM 
dNTP, 2 mM MgSO4, 0.2 µM forward primer, 0.2 µM reverse primer, 1.0 units platinum Taq 
high fidelity DNA polymerase, and 200 ng plasmid or PCR product. All PCR reactions 
containing primers were run at 94 °C for 2 minutes to denature, followed by 30 cycles of 94 °C 
for 30 seconds, 50 °C for 30 seconds, and 68 °C for 1 minute, and then a final round of 68 °C for 
10 minutes. Nested PCR reactions without primers used to clone No TG reaction 2 ran for only 
15 cycles under the same conditions. Final PCR products were run on a 2% agarose gel, purified 
with the Invitrogen PureLink Quick Gel Extraction & PCR Purification Combo kit, and inserted 
into the pCR®2.1-TOPO® TA cloning plasmid vector according to the New England BioLabs 
Fwd primer Δ5’ Region 
Rev primer with BglII site
TGn
ACn
Fwd primer Δ5’ Region & TG 
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(NEB) T4 DNA Ligase protocol (Figure 5). The ligated recombinants were transformed into 
competent One Shot® E. coli cells and grown on ampicillin plates spread with 40 µL of 40 
mg/mL X-Gal. Blue-White screening was used to select colonies that contain successfully 
inserted PCR product. White colonies were cultured in LB broth, mini-prepped, digested with 
EcoRI, and examined on a 1% agarose gel to determine if the correct size construct was present. 
Vectors of the correct size and orientation were cut out of the cloning vector with BglII and 
Acc65I, band isolated, purified using the Invitrogen PureLink Quick Gel Extraction & PCR 
Purification Combo Kit, and inserted into pGL3 via sticky-end ligation according to the NEB T4 
DNA Ligase protocol (Figure 5). Recombinant pGL3 vectors were transformed into competent 
E. coli cells, mini-prepped, digested with Acc65I and BglII, and run on a 1% agarose gel to 
ensure that the expected constructs were successfully inserted prior to sending them for 
sequencing. All recombinant plasmids were sequenced at the Plant-Microbe Genomics Facility at 
Ohio State University. Sequencing reactions were analyzed using NCBI Blast and the 4Peaks 
chromatogram tool. Constructs with confirmed sequences were maxi prepped using the 
Invitrogen PureLink HiPure Plasmid Filter Maxi Prep Kit and DNA concentrations were 
calculated with Qubit Fluorometer.  
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Figure 5. Cloning strategy for NOSI promoter constructs. PCR products with adenine 
overhangs were inserted into the pCR®2.1-TOPO® vector and ligated to its thymine overhangs. 
If correctly inserted, the PCR product will disrupt transcription of the lacZα gene, allowing for 
Blue-White selection. Correctly ligated recombinants were digested with Acc651 and BglII, and 
the NOSI promoters were ligated into the KpnI and BglII sites of the pGL3-Basic vector. 
 
Cell Line Maintenance: 
SK-N-MC cells were grown in Eagles Modified Minimal Medium (EMEM) 
supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum, and 100 units /mL 
penicillin/streptomycin. HeLa cells were grown in DMEM high glucose media with 2mM L-
glutamine, 10% (v/v) fetal bovine serum, and 100 units/mL penicillin/streptomycin. SK-N-MC 
cells were maintained at 37 ˚C with 5% CO2.  
Transfection of Cell Lines:  
1.25 x 106 SK-N-MC cells or 3.0 x 105 HeLa cells were seeded on 6-well plates 24 hours 
prior to transfection. Reporter gene constructs with NOSI promoters were transfected into SK-N-
MC or HeLa cells, which endogenously express high levels of tau and low levels of alpha-
synuclein. To knock down tau expression, cells were transfected with iTau (Santa Cruz), an 
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siRNA known to knock-down tau. An siRNA not known to knock down any human gene was 
used as a control. Alpha-synuclein overexpression was achieved by transfecting a pSI-WTsyn 
plasmid containing the alpha-synuclein gene donated from B.T. Hymen into cells. An empty pSI-
WTsyn plasmid was used as a control. All cells were cotransfected with Beta-galactosidase 
plasmid, pNassβ, to normalize for transfection efficiency. The pGL3-Control vector with SV40 
promoter and SV40 enhancer was utilized as a highly expressing positive control for luciferase 
assays, and the pGL3-Basic plasmid with no inserted promoter was utilized as the negative 
control. DNA quantities utilized in each transfection are found in Table 2. Cells with no 
luciferase or beta-galactosidase transfected were utilized to normalize for background light 
values in both assays.  
Table 2. Quantities of DNA utilized in each transfection.  
Construct Tau assay Alpha-synuclein assay 
Reporter gene construct 5 µg 3.5 µg 
Beta-galactosidase 3 µg 3.5 µg 
iTau 1.8 X 10-4 µMoles -- 
siRNA 1.8 X 10-4 µMoles -- 
pSI-WTsyn -- 3.5 µg 
Control alpha-synuclein -- 3.5 µg 
	  
SK-N-MC transfections were done using both the Lipofectamine 2000 and Mirus Bio 
Trans-IT X2 protocols, while HeLa transfections were performed only with Trans-It X2. Cells 
were incubated for 24 hours after transfection at 37 C with 5% CO2. To harvest, transfected cells 
were rinsed with sterile PBS and spun at 5000 g for 5 minutes. Dry pellets were stored at –80 C 
for up to 1 week prior to assaying. These pellets were re-suspended in 300 µL 0.25 M Tris-HCl. 
To lyse the cells, each tube was sonicated at amplitude 60 on ice for 7 pulses no more than 1 
second long. Lysed cells were spun at 13000 g for 10 minutes at 4 C. The supernatant contained 
the gene products of interest.  
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Luciferase Assay:  
Luciferase was used as a reporter gene to measure gene expression directed by our cloned 
NOSI promoters. For each sample, a Berthold Detection Systems SIRIUS luminometer injected 
100 µL of luciferin into a cuvette containing 350 µL of substrate and 40 µL of cell extract. The 
proportions for the substrate include 0.5 volume of 50mM gly-gly pH 7.8, 0.25 volume 
of10mg/mL ATP pH 6-8, 0.10 volume of 150 mM MgSO4, and 0.15 volume of H2O. The 
luminometer reports luciferase activity in relative light units (RLU). 
Protein Assay:  
The protein assay was used to normalize for the number of cells in each sample. One 
milliliter of room temperature Bio-Rad Protein Reagent Dye (1 part filtered dye to 4 parts water 
stock) was added to a cuvette for each sample followed by either five microliters of protein 
standards at 0.0, 0.125, 0.25, 0.5, 0.75, 1.0, 1.25, and 1.47 mg/mL or ten microliters of cell 
extract. Absorbance was measured at 595 nm. 
Beta-Galactosidase Assay:  
Beta-galactosidase (Bgal) assays were used to normalize for transfection efficiency. Each 
reaction contained 60 μL of cellular extract, 3 μL of 100X Mg solution (0.1 M MgCl2, 4.5 M 
beta-mercaptoethanol), 66 μL of 1X ONPG (a 4 mg/mL solution of o-nitrophenyl-β-D-
galactopyranoside dissolved in 0.1 M sodium phosphate), and 151 of μL 0.1 M sodium 
phosphate at pH 7.5 (41 mL 0.2 M Na2HPO4 * 2H2O, 9 mL 0.2 M NaH2PO4- * 2H2O, and 50 mL 
H2O). Reactions were incubated at 37 °C for 60 minutes or until a faint yellow color developed. 
Reactions were stopped with 500 μL of 1.0 M sodium bicarbonate and measured in a 
spectrophotometer at 420 nm.  
 
	   18	  
Data Analysis:  
 Expression was recorded as mean relative light units (RLU) per unit of beta-galactosidase 
(Bgal Unit) activity per minute ± standard deviation. Expression fold-changes were calculated 
between high and low tau or alpha-synuclein, and two-tailed t-tests were performed to determine 










































The ΔTG, Δ5’ Region, and Δ5’ Region & TG constructs were made to examine whether 
the TGm(TA)TGn repeat in the NOSI 1f promoter may be a binding site for tau and alpha-
synuclein to regulate NOSI gene transcription. The constructs were first made from PCR on the 
NOSI Full Promoter template and were cloned into the pCR®2.1-TOPO® cloning vector. 
Insertion into the cloning vector was verified as correct by digesting plasmids with EcoRI and 
observing the expected 1810 bp fragment of ΔTG, 364 bp fragment of Δ5’ Region, and 299 bp 
fragment of Δ5’ Region & TG. Correct plasmids were cut with BglII and Acc65I, inserted into 
the pGL3 reporter gene vector.  
When the ΔTG construct was inserted into pGL3, we observed the expected 4818 bp 
fragment from pGL3 and a smaller 1795 bp ΔTG promoter fragment upon digestion with BglII 
and Acc651 (Figure 6). The Δ5’ Region construct was obtained in the pCR®2.1-TOPO® cloning 
vector from previous lab work by Kristen Grathwald  (Rife et al., 2009). Upon digestion of Δ5’ 
Region in pGL3 with Acc651 and BglII, we observed the expected 4818 bp fragment and the 349 
bp fragment containing the Δ5’ Region promoter (Figure 6). Finally, the expected 4818 bp and 
284 bp fragments of the Δ5’ Region & TG construct were observed upon digestion with Acc651 
and BglII (Figure 6). The completed plasmids are 6582 bp, 5167 bp, and 5102 bp for ΔTG, Δ5’ 
Region, and Δ5’ Region & TG, respectively. 
Once restriction enzyme digests confirmed the intended plasmid design, the constructs 
were sequenced by the Ohio State Plant Microbe Genome Facility. The resulting sequences were 
blasted against our expected sequence for each plasmid, and we determined that each plasmid 
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Figure 6. Gel evidence of insertion of NOSI promoter constructs ΔTG, Δ5’ Region, and Δ5’ 
Region & TG into reporter gene vector pGL3. All pGL3 vectors containing the correct NOSI 
promoter were digested with BglII and Acc65I overnight at 37 °C. Lane 1 contains the pGL3 
vector and the ΔTG promoter. Lane 2 contains a 500 bp molecular weight ladder, whose band 
sizes are marked on the left side of the gel in base pairs. Lane 3 contains pGL3 vector and the 
Δ5’ Region promoter, and lane 4 contains pGL3 and the Δ5’ Region & TG promoter. Lane 5 
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Effect of tau knock-down on NOSI promoter activity in SK-N-MC cells: 
 
 Constructs Full Promoter, Δ5’ Region, and Δ5’ Region & TG were transfected into SK-
N-MC cells, along with either iTau or control siRNA and luciferase expression assays were 
performed to examine whether tau is mediating expression changes through the (TG)mTA(TG)n 
repeat. Following tau knockdown, Full Promoter directed 8365.5 ± 540.1 RLU/Bgal Unit while 
this construct expressed 4535.8 ± 292.4 RLU/Bgal Unit at high tau levels (Figure 7). Therefore, 
tau knockdown induced a 1.84-fold increase in expression (p = 0.014) of a reporter gene directed 
by the Full Promoter construct. The Δ5’ Region construct exhibited a 1.63-fold increase in 
expression (p = 0.002) with RLU/Bgal Unit values of 5461.7 ± 387.3 and 3360.5 ± 2.349 for low 
and high tau levels, respectively (Figure 7).  Construct Δ5’ Region & TG had a 1.01-fold change 
in expression (p = 0.918), with low tau conditions yielding 2991.2 ± 133.8 RLU/Bgal Unit and 
high tau conditions yielding 3009.0 ± 306.1 RLU/Bgal Unit. Two additional assays of tau 
knockdown with the Full Promoter yielded a 1.40-fold (p = 0.057) and a 1.82-fold (p = 0.0003) 
increase in expression. The assay yielding a 1.40-fold change was calculated using RLU values 
from the tau knockdown and no siRNA conditions. Subsequent experiments with Δ5’ Region 
construct yielded 1.50-fold (p = 0.050) and 1.68-fold (p = 0.002) increases in expression, while 
the Δ5’ Region & TG construct yielded 1.05-fold (p = 0.984) and 1.02-fold (p = 0.263) increases 
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Figure 7. The effect of tau knock-down on NOSI promoter activity in SK-N-MC cells. NOSI 
1f promoter reporter gene constructs were transfected into SK-N-MC cells with beta-
galactosidase and either iTau or a control siRNA not known to knock down any human gene. 
The results of the luciferase assays were presented as relative light units (RLU) over units of 
beta-galactosidase activity per minute. Data represent the average values for three repeated trials. 
Error bars represent one standard deviation, and a * indicates constructs that were significantly 
different from controls in a t-test (p < 0.05).  
 
Effect of alpha-synuclein overexpression on NOSI promoter activity in SK-N-MC cells:  
The Full Promoter, construct Δ5’ Region, and construct Δ5’ Region & TG were 
transfected into SK-N-MC cells along with either an alpha-synuclein overexpression vector or a 
control vector, and luciferase expression assays were performed to examine whether alpha-
synuclein is mediating expression changes through the (TG)mTA(TG)n repeat. The Full Promoter 
had expression values of 4264.0 ± 352.5 and 2054.9 ± 243.0 RLU/Bgal Unit for conditions of 
low and high alpha-synuclein, respectively, demonstrating a 2.07-fold decrease in expression (p 
= 0.022) upon alpha-synuclein overexpression (Figure 8). The Full Promoter displayed a 2.18-
fold (p = 0.048) and a 2.08-fold (p = 0.012) decrease in expression upon two subsequent trials of 
alpha-synuclein overexpression. The Δ5’ Region promoter directed expression levels of 3037.0 ± 
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185.1 RLU/Bgal Unit under low alpha-synuclein conditions and 1437.4 ± 329.6 RLU/Bgal Unit 
under high alpha-synuclein conditions, resulting in a 2.11-fold decrease in expression (p = 0.033)     
(Figure 8). On the other hand, no changes in expression were observed in construct Δ5’ Region 
& TG. At low alpha-synuclein levels, the Δ5’ Region & TG construct directed 2839.1 ± 202.0 
RLU/Bgal Unit, and at high alpha-synuclein levels, the Δ5’ Region & TG promoter directed 
2798.1 ± 236.7 RLU/Bgal Unit, accounting for a 1.01-fold change in expression (p = 0.892) 
(Figure 8). The Δ5’ Region & TG promoter also directed 0.99-fold change in expression in two 
subsequent experiments (p = 0.880).  
 
 
Figure 8. The effect of alpha-synuclein overexpression on NOSI promoter activity in SK-N-
MC cells. NOSI 1f promoter constructs were cloned in front of luciferase in the pGL3 reporter 
gene vector (Promega).  NOSI reporter gene constructs into SK-N-MC cells with beta-
galactosidase and either an alpha-synuclein overexpression vector (pSI-WTsyn) or a control 
vector.  The results of luciferase assays are presented as relative light units (RLU) over units of 
beta-galactosidase activity per minute. Data represent the average values for three repeated trials. 
Error bars represent one standard deviation, and an * indicates constructs that were significantly 
different from controls in a t-test (p < 0.05).  
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Effect of alpha-synuclein overexpression on NOSI promoter activity in HeLa cells:  
To examine the role of alpha-synuclein in the regulation of the NOSI promoter in a 
different cell line, we optimized the protocol for HeLa cells and performed a single trial using.  
We determined that the following conditions were optimal for experiments with HeLa cells:  
§ Seed cells at a concentration of 3.0x105 cells per well, rather than 1.25x106 cells per well 
§ Add TransIT-X2 reagent in a 2:1 TransIT-X2:ng DNA ratio in HeLa rather than a 3:1 ratio 
§ Thoroughly mix the transfection reagent, DNA, and media prior to the incubation period by 
pipetting the entire volume up and down 
§ Incubate transfection reagent, DNA, and media for 15 minutes at room temperature before 
adding to cells  
§ Utilize 40 µL cell extract for luciferase assays and 60 µL cell extract for beta-galactosidase 
assays  
 
We transfected only the Full Promoter construct and construct Δ5’ Region & TG into 
HeLa cells along with either an alpha-synuclein overexpression vector or a control vector, and 
the constructs expressed at higher levels than in SK-N-MC. The Full Promoter construct 
displayed a 2.23-fold increase in expression (p<0.05) when alpha-synuclein was overexpressed 
(Figure 9), whereas alpha-synuclein overexpression was associated with a decrease in expression 
in SK-N-MC cells (Figure 8).  Additionally, expression driven by the Δ5’ Region & TG promoter 
construct increased 2.81-fold (p<0.05), despite the absence of the (TG)mTA(TG)n repeat (Figure 
9).  
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Figure 9. The effect of alpha-synuclein overexpression on NOSI promoter activity in HeLa 
cells. NOSI 1f promoter constructs were transfected into HeLa cells with beta-galactosidase and 
either an alpha-synuclein overexpression vector (pSI-WTsyn) or a control vector.  The results of 
luciferase assays are presented as relative light units (RLU) over units of beta-galactosidase 
activity per minute. Data represent the average values for three repeated trials. Error bars 
represent one standard deviation, and an * indicates constructs that were significantly different 
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DISCUSSION 
 
 To examine whether tau and alpha-synuclein are modulating transcription of the NOSI 
gene at a polymorphic (TG)mTA(TG)n repeat, we measured gene expression driven by variations 
of the NOSI promoter.  A large portion of our project involved cloning these promoter constructs 
into the pGL3 luciferase reporter gene vector. The sequencing output matched our expected 
sequences for constructs ΔTG, Δ5’ Region, and Δ5’Region & TG, so we can reasonably trust 
that all expression data from those constructs did not occur as a result of cloning mutations.  The 
ΔTG construct was not finished in time to put into any assays, but it will be used in the next 
experiments. When tau was knocked down in SK-N-MC cells, the Full Promoter and construct 
Δ5’ Region, which both contain the (TG)mTA(TG)n repeat, displayed a significant increase in 
expression. However, construct Δ5’ Region & TG, which excludes the repeat, displayed no 
significant change in expression in response to tau knockdown. Thus, tau appears to only affect 
gene expression when the (TG)mTA(TG)n repeat is present, which is consistent with our 
predictions.  
Furthermore, when alpha-synuclein was overexpressed in SK-N-MC cells, both the Full 
Promoter and Δ5’ Region displayed approximately 2-fold decreases in expression. However, the 
Δ5’ Region & TG construct that excludes the repeat did not exhibit a significant change in 
expression. Overexpressed alpha-synuclein had no effect on expression when the (TG)mTA(TG)n 
repeat was deleted, suggesting that the (TG)mTA(TG)n repeat may also be necessary for alpha-
synuclein mediated transcriptional changes in SK-N-MC. However, expression levels were low 
for these constructs in SK-N-MC, so it is questionable whether excess alpha-synuclein could 
have further suppressed transcription in the Δ5’ Region & TG construct. Therefore, we tested the 
constructs in HeLa cells, which are known to robustly express our NOSI promoter constructs. 
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Although HeLa cells are a non-neuronal cell line, they express multiple neuronal genes including 
alpha-synuclein, and are frequently used to study neurological conditions such as AD and PD 
(Culvenor et al., 1995; & Liu et al., 2012).  
As we hoped, the Full Promoter and Δ5’ Region & TG constructs expressed at higher 
levels in HeLa than in SK-N-MC. The Full Promoter exhibited a 2.23-fold increase in 
expression in HeLa but a 2.08-fold decrease in expression in SK-N-MC when alpha-synuclein 
was overexpressed. Additionally, the Δ5’ Region & TG construct showed a significant 2.81-fold 
increase in expression in HeLa cells, but showed no change in expression in SK-N-MC cells 
when alpha-synuclein was overexpressed. While it appears that alpha-synuclein is modulating 
NOSI expression in HeLa cells, the (TG)nTA(TG)m repeat may not be required. The differences 
in expression between SK-N-MC and HeLa experiments are likely due to the presence of 
different transcription factors in the cell lines. Alpha-synuclein could be interacting with other 
proteins and transcription factors, and subsequently regulating transcription through a different 
region in the promoter. The data from HeLa experiments will need to be repeated to confirm 
these results because difficulties with cell growth may have affected the results.  
HeLa cells should be incubated with CO2 levels between 5% and 10%; however, our 
incubator consistently displays CO2 levels greater than 10% for unknown reasons. Elevated 
levels of CO2 can induce oxidative stress (McKenna, 2009), and studies have shown that this 
stress increases nuclear levels of alpha-synuclein (Siddiqui et al., 2012). Therefore, it is possible 
that this stress on our cells caused alpha-synuclein to localize to the nucleus, regardless of 
whether or not cells were transfected with alpha-synuclein. If alpha-synuclein is binding to DNA 
in the low alpha-synuclein condition, it would mimic the results of alpha-synuclein 
overexpression. Despite the need for further optimization, our preliminary data is promising in 
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that it indicates that alpha-synuclein overexpression does change the way our promoter 
constructs express.  
Studies have implicated overexpressed alpha-synuclein in causing differential expression 
of genes other than NOSI, one of which is called PGC1-alpha.  PGC1-alpha is a transcriptional 
co-activator involved in the activation of several genes implicated in mitochondrial biogenesis 
and cellular respiration (Siddiqui et al., 2012). Misexpression of PGC1-alpha has been reported 
in the brains of sporadic PD patients (Mallajosyala et al., 2009). Siddiqui et al. (2012) identified 
a CCCCTTCC consensus sequence for alpha-synuclein binding and observed decreased PGC1-
alpha promoter activity upon alpha-synuclein overexpression.  These studies implicate alpha-
synuclein binding in PGC1-alpha expression changes; however, a mechanism has yet to be 
established. Interestingly, the PGC1-alpha promoter construct purchased from Addgene contains 
a 50 bp TG repeat. Currently, our lab is working to corroborate the work of Siddiqui et al. and 
show whether this TG repeat is needed for alpha-synuclein induced changes in PGC1-alpha 
transcription. Our experiment in HeLa cells revealed a 2-fold increase in PGC1-alpha expression 
with overexpressed alpha-synuclein, which is opposite the trend observed by Siddiqui et al and 
in our NOSI experiments with SK-N-MC. The Siddiqui et al. studies were performed in PC12 
cells derived from a pheochromocytoma of the rat adrenal medulla, a tissue that has neuroblastic 
origins. Therefore, overexpressed alpha-synuclein appears to decrease expression of promoter 
constructs in neuronal cell lines, while increasing expression in HeLa cells. Additional studies 
with this construct in HeLa and SK-N-MC cells may reveal whether alpha-synuclein promotes or 
inhibits PGC1-alpha expression in these cells and whether these expression changes are 
mediated through a TG repeat.  
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Although we have not tested it, the ΔTG construct will provide better information on the 
impact of the polymorphic (TG)mTA(TG)n repeat on NOSI promoter expression because it 
contains the entire promoter sequence, including enhancers and repressors that would normally 
be necessary for NOSI gene transcription. Although the (TG)mTA(TG)n repeat has been 
correlated with AD and PD, other TG repeats in the NOSI promoter could be affecting gene 
expression even in the absence of the large repeat. For example, there are two smaller TG repeats 
further upstream in the NOSI 1f promoter: a 16 bp TG repeat starting at bp 848 and a 
(TG)5TA(TG)2 repeat beginning at bp 866 (Figure 10). According to the literature, tau is able to 
bind to purine-pyrimidine repeats as short as 13 bp (Mania et al., 2016). Construct ΔTG may still 
be affected by tau and alpha-synuclein due to these smaller TG repeats. The additional upstream 
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Figure 10. NOSI 1f promoter sequence displaying smaller upstream TG repeats. The dark 
grey highlighted region shows the 16 bp TG repeat beginning at bp 848 as well as the 
TG5(TA)TG2 repeat beginning at bp 866. The light grey highlighted region shows the 
polymorphic repeat that is known to be correlated with AD and PD. 
 
Although it appears that tau and alpha-synuclein are modulating gene expression in the 
NOSI promoter, regulation may not be through direct binding. For a more definitive answer to 
whether tau and alpha-synuclein are binding to the (TG)nTA(TG)m repeat, future studies will 
utilize ChIP-PCR. This procedure crosslinks proteins to DNA and utilizes antibodies to pull 
down either tau or alpha-synuclein with bound DNA. Subsequent qPCR analysis using primers 
specific to the region of the NOSI gene containing the (TG)nTA(TG)m repeat would determine 
whether tau or alpha-synuclein are modulating transcription through direct binding to the repeat.  
ChIP-sequencing performed on a cohort of PD patients demonstrated that alpha-synuclein can 
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bind to the promoter region of genes such as NEDD4, CDC42, and SLC4A5, and that it can 
increase promoter activity of SLC4A5 (Pinho, et al, 2014). We examined the aforementioned 
genes on the UCSC Genome Browser, but we were unable to find any TG repeats longer than a 
few base-pairs within 2,000 base-pairs of the transcriptional start sites. The longest purine-
pyrimidine repeat we found was an 11 bp TA repeat in NEDD4, suggesting that alpha-synuclein 
may be altering gene expression through motifs other than a purine-pyrimidine repeat. Another 
ChIP-sequencing study also identified NEDD4 and CDC42 as major peaks on a list of 238 target 
genes for alpha-synuclein binding in PD (Martins et al., 2011). We aligned the NOSI promoter 
sequence with NEDD4, CDC42, and pGC1-alpha to investigate other potential regulatory 
sequences, and the results can be found in Table 3. We may wish to explore these sequences in 
the future.  
Table 3. Potential regulatory sequences identified based on alignment of NOSI 1f promoter 
with other promoters known to bind alpha-synuclein. The sequence outputs aligned with 
100% identity in NCBI BLAST®.  
 
Alignment Potential Regulatory Sequences 




NOSI to CDC42 5’-GCCTCTTCTCT-3’ 






Although the mechanism by which tau modulates expression of NOSI is still unclear, our 
study indicates that it may be acting at the (TG)mTA(TG)n repeat. Many studies have 
demonstrated that tau can impact gene expression, and there are a variety of suggestions 
regarding its DNA-binding preferences and sequence specificity (Mania et al., 2016). Thus, it is 
important to test tau knockdown in HeLa cells.  One study indicated that tau bound and bent the 
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DNA through electrostatic interactions at AT-rich regions in the minor groove, preferentially at 
sequences of 13 bp or longer (Wei et al., 2008). Another study indicated that tau bound to GC 
rich oligonucleotides in addition to AT-rich regions (Camero et al., 2014). Thus, tau’s binding 
preferences may be based on hydrophobicity or general structure of the backbone as opposed to 
specific sequences (Camero et al., 2014). Because the (TG)mTA(TG)n repeat is capable of 
forming alternative DNA structures, we believe that the polymorphic repeat is worth pursuing in 
future investigations.  
The cellular mechanisms involved in neurodegeneration are complex, and animal models 
are critical to better understanding and treating the associated diseases. Animal models of AD 
and PD have focused heavily on the role of intracellular neuronal plaques and tangles; however, 
these rodent models have provided us with limited success in developing new clinical treatments 
and in demonstrating how neurofibrillary tangles contribute to disease pathology (Howell, 2015). 
In addition to our work discussed in this paper, we also generated a promoter construct with an 
extra short (TG)4TA(TG)2 repeat for future use in the lab (Appendix 2). This construct was 
modeled after the very short (TG)mTA(TG)n repeat found in the NOSI promoter of mice and rats. 
If this construct responds to alpha-synuclein and tau less significantly than the human Full 
Promoter constructs, it may indicate that shorter purine-pyrimidine repeats in rodents make them 
less susceptible to pathological changes in gene expression. These discrepancies in gene 
expression could explain the shortcomings of current rodent models.  
Currently, there are no cures for either Alzheimer’s Disease or Parkinson’s Disease, and 
there are limited treatments to inhibit their progression. Protein modulation of NOSI gene 
expression may only be a small piece of the complex cellular machinery that goes awry in 
devastating neurodegenerative diseases. However, understanding this mechanism may point to a 
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novel role for the proteins that have been implicated in these diseases. Furthermore, this study 
may further expand our knowledge about the ways in which purine-pyrimidine repeats as well as 
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APPENDICES 
 
APPENDIX  1. Sequencing output from Ohio State University Plant-Microbe Genomics 
Facility for cloned NOSI promoter constructs in pGL3.  
 
Table a. Sequencing results for ΔTG construct. The final plasmid contains the entire pGL3 
vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR product in 
green.   
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Table b. Sequencing results for the Δ5’ Region construct. The final plasmid contains the entire 
pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR product 
in green.  	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Table c. Sequencing results for the Δ5’ Region & TG construct.  The final plasmid contains the 
entire pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR 
product in green.  	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APPENDIX 2: Cloning strategy for the rodent construct containing (TG)4TA(TG)2 
polymorphism. 
We have already conducted cloning and sequencing for the construct containing a 
(TG)4TA(TG)2 repeat, modeled after the extra short polymorphism in the rodent NOSI promoter. 
We refer to this construct as the Rodent construct. The Rodent construct required three rounds 
of PCR, similar to the strategy for ΔTG (Figure 3). Reaction 1a uses forward primer 
GGGGTACCAAGCTTGTGCTCCCAGAG and reverse primer 
GAAACACATACACACACAATGACAATTTCTGG. Reaction 1b uses forward primer 
CATTGTGTGTGTATGTGTTTCCTGATAGAAA and reverse 
primer CACTCCTCGATGAATCGCGTCTAGAAG. Reaction 3 uses forward primer 
GGGGTACCAAGCTTGTGCTCCCAGAG, and reverse primer GGAAAATGACA 
ATTTCTGGGAG.  The Rodent construct was cloned into pGL3 and sequenced. The final 
expected plasmid was 6679 bp. However, we found a discrepancy between sequencing reaction 2 
and our expected Rodent sequence (Table d). The highlighted region of Table d shows only 
two cytosines (C) rather than the expected three C's. The discrepancy does not appear in the 
other two sequencing reactions because they do not cover that region. The chromatogram 
corroborates the error, but it is possible that the deletion resulted from a sequencing error 
rather than a cloning error. An additional sequencing reaction is needed to confirm this 
result. Future studies must be done to examine whether Rodent contains a true mutation 
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Table d. Sequencing results for the Rodent construct containing (TG)4TA(TG)2 polymorphism. The final 
plasmid contains the entire pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue, 
and the PCR product in green. The highlighted region contains a discrepancy between our expected 
sequence and sequencing reaction 2.  	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